AOK Rheinland-Pfalz/Saarland - Die Gesundheitskasse

Germany – Medicines – Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active ingredient imiquimod (D06BB10) within the framework of a so-called open-house model.

Germany – Pharmaceuticals – Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for pharmaceuticals containing the active ingredient Clobetasol (D07AD01) within the framework of a so-called open-house model.

Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active substance edoxaban (B01AF03) within the framework of a so-called open-house model.

Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active substance olanzapine (N05AH03), excluding solid oral dosage forms, within the framework of a so-called open-house model.

Germany – Pharmaceuticals – Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for pharmaceuticals containing the active ingredient olanzapine (N05AH03), excluding fixed oral dosage forms, within the framework of a so-called open-house model.

Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products with the active ingredient vaginal ring with progestogens and estrogens (G02BB01) within the framework of a so-called open-house model.

Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active ingredient filgrastim (L03AA02) within the framework of a so-called open-house model.

Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active substance ebastine (R06AX22) within the framework of a so-called open-house model.

Conclusion of non-exclusive discount agreements pursuant to §§ 130a (8)/130c (1) SGB V for medicinal products containing the active substance golimumab (L04AB06) within the framework of a so-called open-house model.

Germany – Pharmaceuticals – Conclusion of Non-Exclusive Discount Agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for Pharmaceuticals containing the active substance Edoxaban (B01AF03) within the framework of a so-called Open-House Model.

Germany – Pharmaceuticals – Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for pharmaceuticals containing the active substance dexamethasone (S01BA01), implants only within the framework of a so-called open-house model.

Germany – Pharmaceuticals – Conclusion of non-exclusive rebate agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for pharmaceuticals containing the active substance bosutinib (L01EA04) within the framework of a so-called open-house model.

Germany – Pharmaceuticals – Conclusion of non-exclusive rebate agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for pharmaceuticals containing the active ingredient ebastine (R06AX22) within the framework of a so-called open-house model.

Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active substance clobetasol (D07AD01) within the framework of a so-called open-house model.

Germany – Pharmaceuticals – Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for pharmaceuticals containing the active ingredient filgrastim (L03AA02) within the framework of a so-called open-house model.

Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active substance dexamethasone (S01BA01), implants only within the framework of a so-called open-house model.

Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active substance bosutinib (L01EA04) within the framework of a so-called open-house model.

Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicines containing the active ingredient filgotinib (L04AF04) within the framework of a so-called open-house model.

Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active substance sultiame (N03AX03), film-coated tablets only, within the framework of a so-called open-house model.

Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicines containing the active ingredient erythropoietin (B03XA01) within the framework of a so-called open-house model.

Germany – Medicines – Conclusion of non-exclusive discount agreements pursuant to §§ 130a Abs. 8/130c Abs. 1 SGB V for medicines containing the active ingredient sulfasalazine (M01CX02) within the framework of a so-called open-house model.

Germany – Pharmaceutical Products – Conclusion of Non-Exclusive Rebate Agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for Pharmaceutical Products containing the Active Ingredient Filgotinib (L04AF04) within the Framework of a So-Called Open-House Model.

Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active substance sulfasalazine (M01CX02) within the framework of a so-called open-house model.

Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products with the active ingredient imiquimod (D06BB10) within the framework of a so-called open-house model.

Germany – Pharmaceuticals – Conclusion of non-exclusive rebate agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for pharmaceuticals containing the active ingredient golimumab (L04AB06) in the context of a so-called open-house model.

Germany – Pharmaceuticals – Conclusion of non-exclusive rebate agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for pharmaceuticals containing the active ingredient erythropoietin (B03XA01) within the framework of a so-called open-house model.

Germany – Pharmaceuticals – Conclusion of non-exclusive rebate agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for pharmaceuticals containing the active substance vaginal ring with progestins and estrogens (G02BB01) within the framework of a so-called open-house model.

Germany – Pharmaceuticals – Conclusion of non-exclusive rebate agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for pharmaceuticals containing the active ingredient Sultiam (N03AX03), film-coated tablets only within the framework of a so-called open-house model.

Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active ingredient clobetasol (D07AD01) within the framework of a so-called open-house model.

Conclusion of non-exclusive discount agreements pursuant to §§ 130a para. 8/130c para. 1 SGB V for medicinal products containing the active substance edoxaban (B01AF03) within the framework of a so-called open-house model.